Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$14.97
$0.18(1.32%)
At close: 4:00 PM EDT
$14.97
$0.18(1.32%)
Day’s Range― - ―
52-Week Range$8.63 - $26.19
Previous CloseN/A
Volume207.11K
Average Volume (3M)380.45K
Market Cap
$629.25M
Enterprise Value$1.09B
Total Cash (Recent Filing)$174.90M
Total Debt (Recent Filing)$21.00M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Oct 28, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding62,877,760
10 Day Avg. Volume430,269
30 Day Avg. Volume380,449
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-254.53
Enterprise Value/Ebitda-6.47
Forecast
1Y Price Target
$42.50Price Target Upside183.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$2.66M
Bulls Say, Bears Say
Bulls Say
Proprietary Viaskin PlatformThe proprietary Viaskin patch gives DBV a differentiated delivery platform focused on food allergies and immune-related conditions. If clinical and regulatory objectives are achieved, the technology could support multiple indications and create a durable foundation for future product development.
FDA Regulatory ProgressFDA engagement without a request for additional data reduces one potential source of development uncertainty and supports progress toward a BLA submission. This regulatory advancement strengthens the lead program’s medium-term path, although approval and commercialization remain future milestones.
Low Financial LeverageLow debt relative to equity and a sizable asset base mean DBV is not currently burdened by heavy leverage. This provides greater flexibility than a debt-stressed balance sheet while the company advances development, even though ongoing losses may still require additional capital.
Bears Say
No Current Commercial RevenueThe return to zero revenue indicates that DBV has not established meaningful commercial scale and remains dependent on development progress rather than recurring product sales. This limits internal funding capacity and leaves future financial performance highly dependent on successful clinical and regulatory execution.
Widening Net LossesLosses have expanded materially while revenue remains absent, showing that operating expenditures continue to exceed any inflows by a wide margin. Persistent negative profitability can erode equity, increase reliance on external financing, and constrain DBV’s ability to sustain its pipeline independently.
Accelerating Cash BurnThe sharp deterioration in operating and free cash flow indicates that DBV is consuming capital at an accelerating rate. Because free cash flow broadly tracks net losses, the deficit reflects a recurring funding requirement that could increase dilution or limit development investment over time.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $8.63 and its highest was $26.18 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $629.25M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Oct 28, 2026 which is tomorrow.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Jul 16, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.012.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.18.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 62,877,760 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went down -1.077%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.50 (183.90% Upside)
$42.50 (183.90% Upside)
Blogger Sentiment
Bullish
DBVT Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 689.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.23%
12-Months-Change
Fundamentals
Return on Equity
-119.47%
Trailing 12-Months
Asset Growth
55.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBVT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant progress in Viaskin Peanut development and financial management. However, regulatory challenges and increased operating expenses pose some concerns. The overall sentiment is cautiously optimistic with a positive tilt due to successful trial milestones and extended cash runway.View all DBVT earnings summariesDBVT Stock 12 Month Forecast
Average Price Target
$42.50
▲(183.90% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
58.85% Insiders
2.29% Mutual Funds
27.52% Other Institutional Investors
11.32% Public Companies and
Individual Investors